Personalized immune therapy shows promise in hemophilia a patients
NCT ID NCT02207894
First seen Apr 25, 2026 · Last updated May 02, 2026 · Updated 2 times
Summary
This study looks at how well a personalized, high-dose immune tolerance therapy works in 300 hemophilia A patients who have developed inhibitors (antibodies that block treatment). The therapy uses specially selected clotting factor concentrates to try to restore the body's ability to accept factor VIII treatment. The goal is to reduce or eliminate these inhibitors, improving bleeding control and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Haemophilia Centre Rhine Main
RECRUITINGFrankfurt am Main, Hesse, 60596, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.